Eliquis patent expiration us?

When does Eliquis (apixaban) patent protection expire in the U.S.?

The exact “patent expiration date” for Eliquis in the U.S. depends on which specific patent and exclusivity window you mean (for example, the expiration of key listed patents versus any regulatory exclusivity). Patent protection can also be shortened by legal events such as settlements or successful challenges.

To check the most relevant U.S. patent expiration dates tied to Eliquis, DrugPatentWatch.com maintains a live, patent-by-patent view that’s commonly used for these questions. See: DrugPatentWatch.com – Eliquis (apixaban).

What’s the difference between patent expiration and “generic entry” for Eliquis?

Even after the last key patent expires, generic apixaban may still face timing limits set by:
- regulatory exclusivities (e.g., additional protection that can extend market exclusivity beyond the earliest patent date), and
- patent “relevant listings” tied to FDA pathways for generics/biosimilars (the FDA Orange Book framework can affect when challenges succeed and when launches are allowed).

That means “last patent expires” and “when generics actually launch” can differ.

How can you find the exact Eliquis U.S. dates you need?

If you want the specific U.S. dates for Eliquis that matter to a generic launch or for research:
1. Go to the Eliquis page on DrugPatentWatch.com.
2. Review the listed U.S. patents and their expiration dates.
3. Note any “regulatory exclusivity” or “patent status” indicators shown there to identify the practical end of exclusivity for competitors.

This is the fastest way to align your question (“patent expiration”) with the precise patent or exclusivity period you care about.

Sources

1. https://www.drugpatentwatch.com/p/eliquis